CNTX

Context Therapeutics' stock price has increased by 61.9% since January 1, 2026. CTIM-76 received FDA Fast Track Designation for platinum-resistant ovarian cancer on April 2, 2026. The company reported a net loss of $8.7 million in Q1 2026, with cash reserves expected to last into mid-2027. Phase 1a interim clinical data for CTIM-76 is expected in June 2026 and for CT-95 in September 2026. A Phase 1 clinical trial for CT-202 is expected to begin in Q3 2026, following regulatory approvals in Australia. The company presented at several healthcare conferences in March 2026. In May 2024, Context Therapeutics announced a private placement expected to generate $100.0 million, extending its cash runway into 2028.